Multiple endocrine neoplasia type 1 (MEN-1) is a rare genetic disorder characterized by combined lesions of the endocrine system, usually in the form of adenomas or carcinomas affecting the parathyroid glands, pancreas and pituitary gland. The pathology is associated with a mutation in the MEN1 gene, which encodes the menin protein, which is involved in the regulation of cell growth and division. This disease is hereditary and transmitted in an autosomal dominant manner. Patients with MEN-1 may exhibit a wide range of clinical symptoms, which complicates diagnosis and requires careful monitoring to prevent severe complications, such as tumor metastasis and endocrine insufficiency.
History of the disease and interesting historical facts
Multiple endocrine neoplasia type 1 was first described in 1954 by endocrinologist Paul M. Lipp. The field of MEN-1 research began to develop rapidly due to the efforts of various medical institutions and research groups seeking to understand the genetic nature of the disease. In 1990, scientists isolated the MEN1 gene associated with the disease, which opened up new horizons for the diagnosis and treatment of patients. Historically, it is important to note that the development of molecular genetics has significantly increased the level of understanding of the mechanisms underlying MEN-1 and facilitated the creation of genetic screening methods to identify predisposed patients.
Epidemiology
The prevalence of multiple endocrine neoplasia type 1 is estimated to be approximately 1 in 30,000 individuals, but actual numbers may vary by geographic region and ethnicity. Although MEN1 is a rare disorder, its combination with other endocrine disorders may result in more cases than initially thought. Of particular note is that patients with a family history of the disorder have a significantly increased risk of developing symptoms. Studies have shown that approximately 30% of MEN1 patients have a family history, indicating the importance of genetic counseling.
Genetic predisposition to this disease
Multiple endocrine neoplasia type 1 is associated with mutations in the MEN1 gene, located on chromosome 11. This gene encodes the menin protein, which plays a key role in cell cycle regulation and has an effect on apoptosis and cell proliferation. Analysis of MEN1 gene mutations has shown that the most common mutations include deletions, substitution points, and insertions. Approximately 90% patients diagnosed with MEN-1 have identifiable mutations in MEN1. It should be noted that the presence of a gene mutation does not always lead to disease manifestation, which is associated with the influence of external and internal factors.
Risk factors for the development of this disease
Among the risk factors that contribute to the development of multiple endocrine neoplasia type 1, the following are distinguished:
- Heredity: Having affected family members significantly increases the likelihood of developing the disease.
- Co-morbidities: For example, the presence of other endocrine disorders may be a sign of predisposition.
- Environmental factors: Although their influence has not been clearly established, some studies suggest that exposure to toxic substances may play a role.
- Age: The onset of clinical manifestations is most often observed between the ages of 20 and 50 years.
- Gender: No significant differences in the incidence of the disease were found between men and women.
Diagnosis of this disease
Diagnosis of multiple endocrine neoplasia type 1 is based on clinical, laboratory and radiological studies:
- Main symptoms include hypoparathyroidism, Whipple syndrome, hyperprolactinemia and other endocrine disorders.
- Laboratory tests: determination of hormone levels (insulin, gastrin, calcium, parathyroid hormone) helps to identify endocrine disorders.
- Radiologic tests: Ultrasound, CT, and MRI can be used to visualize tumors in the parathyroid glands and pancreas.
- Other types of diagnostics: genetic testing to detect mutations in MEN1 helps to clarify the diagnosis.
- Differential diagnosis: it is necessary to exclude other syndromes such as MEN-2, seven-fold syndrome and other neoplasias.
Treatment
Treatment for multiple endocrine neoplasia type 1 depends on the specific symptoms and characteristics of the tumors:
- General treatment: regular monitoring and control of hormone levels.
- Pharmacological treatment: may include the use of antagonists to control hyperinsulinism and other endocrine disturbances.
- Surgical treatment: often necessary to remove tumors, especially in cases of malignant transformation or significant enlargement.
- Other treatments: In some cases, radiation therapy or chemotherapy may be indicated.
List of medications used to treat this disease
The following drugs may be used in the treatment of multiple endocrine neoplasia type 1:
- Omeprazole for the control of gastritis and gastrinoma-induced peptic ulcer.
- Calcium channel blockers for the management of hyperparathyroidism.
- Insulin preparations for the control of hyperinsulinemia.
- Bromocriptine to lower prolactin levels.
- Antibiotics in the presence of infectious complications.
Disease monitoring
Monitoring of patients with multiple endocrine neoplasia type 1 includes regular medical examinations and laboratory tests:
- Monitor hormone levels every 6-12 months.
- Routine radiological examinations to assess the condition of tumors.
- Monitoring the development of possible complications such as metastases.
The prognosis of patients depends on the degree of organ involvement and the presence of malignant tumors. The likelihood of developing complications such as hypoparathyroidism and other endocrine deficiencies can significantly affect the quality of life.
Age-related features of the disease
Multiple endocrine neoplasia type 1 can occur in different age groups:
- Childhood and adolescence: clinical manifestations may be less pronounced, but genetic predisposition must be taken into account.
- Young adulthood: most common onset, symptoms may be most severe.
- Old age: the development of complications and a more complex course of diseases associated with age-related changes in the body and an increased risk of concomitant diseases is possible.
Questions and Answers
- How is multiple endocrine neoplasia type 1 diagnosed? Diagnosis is based on clinical analysis, laboratory tests to determine hormone levels and imaging studies.
- Is multiple endocrine neoplasia type 1 a hereditary disease? Yes, the disease has an autosomal dominant inheritance pattern, which implies a high risk of transmission to offspring.
- What are the main treatments for MEN-1? Treatment may include both conservative measures and surgical interventions to remove tumors, as well as hormone replacement therapy.
- What is the prognosis for patients with multiple endocrine neoplasia type 1? The prognosis depends on the nature of the tumors and the timeliness of diagnosis; active monitoring can improve quality of life and avoid serious complications.
- At what age does the disease most often appear? Clinical manifestations usually begin in young adulthood, most often between 20 and 50 years of age.
